Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment

Brown, J. R., Eichhorst, B., Hillmen, P., Jurczak, W., Kaźmierczak, M., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Zhou, K., Simkovic, M., Mayer, J., Gillespie-Twardy, A., Ferrajoli, A., Ganly, P. S., Weinkove, R., Grosicki, S., Mital, A., Robak, T., … Shadman, M. (2023). Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment. Future Oncology, 20(12), 717–726. https://doi.org/10.2217/fon-2023-0849
Authors:
Jennifer R. Brown
Barbara Eichhorst
Peter Hillmen
Wojciech Jurczak
Maciej Kaźmierczak
Nicole Lamanna
Susan O’Brien
Constantine S. Tam
Lugui Qiu
Keshu Zhou
Martin Šimkovič
Jiří Mayer
Amanda Gillespie-Twardy
Alessandra Ferrajoli
Peter Ganly
Robert Weinkove
Sebastian Grosicki
Andrzej Mital
Tadeusz Robak
Anders Österborg
Habte A. Yimer
Tommi Salmi
Megan-Der-Yu Wang
Lina Fu
Jessica Li
Kenneth K. Wu
Aileen Cohen
Mazyar Shadman
Affiliated Authors:
Nicole Lamanna
Columbia Affiliation:
Subjects:
Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.2217/fon-2023-0849
PMID:
39132937
DOI:
10.2217/fon-2023-0849
Journal:
Future Oncology
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: